NasdaqCM - Nasdaq Real Time Price USD

Viridian Therapeutics, Inc. (VRDN)

Compare
22.75 -0.58 (-2.49%)
At close: September 30 at 4:00 PM EDT
23.63 +0.88 (+3.87%)
After hours: September 30 at 7:54 PM EDT
Loading Chart for VRDN
DELL
  • Previous Close 23.33
  • Open 22.75
  • Bid 22.71 x 500
  • Ask 22.82 x 300
  • Day's Range 22.14 - 23.53
  • 52 Week Range 10.93 - 24.18
  • Volume 863,328
  • Avg. Volume 1,479,263
  • Market Cap (intraday) 1.737B
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) --
  • EPS (TTM) -4.25
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.56

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

www.viridiantherapeutics.com

94

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VRDN

View More

Performance Overview: VRDN

Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VRDN
4.45%
S&P 500
20.81%

1-Year Return

VRDN
48.31%
S&P 500
34.38%

3-Year Return

VRDN
33.82%
S&P 500
32.18%

5-Year Return

VRDN
96.46%
S&P 500
94.56%

Compare To: VRDN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VRDN

View More

Valuation Measures

Annual
As of 9/30/2024
  • Market Cap

    1.74B

  • Enterprise Value

    1.39B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.31k

  • Price/Book (mrq)

    5.27

  • Enterprise Value/Revenue

    4.81k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.45%

  • Return on Equity (ttm)

    -53.97%

  • Revenue (ttm)

    288k

  • Net Income Avi to Common (ttm)

    -228.06M

  • Diluted EPS (ttm)

    -4.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    571.37M

  • Total Debt/Equity (mrq)

    4.27%

  • Levered Free Cash Flow (ttm)

    -87.13M

Research Analysis: VRDN

View More

Company Insights: VRDN

Research Reports: VRDN

View More

People Also Watch